Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
MHLW Official Warns of High Risks from GLP-1 Use in Cosmetic Weight Loss
A senior health ministry official warned on June 18 that the off-label use of diabetes drugs such as GLP-1 receptor agonists for cosmetic weight loss carries significant risks, as Japan continues to grapple with the inappropriate use of the increasingly…
To read the full story
Related Article
- MHLW Issues Guidance on Proper Use of GLP-1 Drugs
June 17, 2026
- Lilly Warns Against Off-Label Use of Mounjaro
June 11, 2026
- Japan Tightens Oversight of Mounjaro Resales: Health Minister
June 8, 2026
- Three Sent to Prosecutors over Alleged Illegal Mounjaro Sales
June 3, 2026
REGULATORY
- More Company Involvement in CEA a Big Positive: C2H Researcher
September 29, 2026
- Japanese Red Cross Preps for Lifting of Europe-Linked Blood Donation Curbs
September 29, 2026
- PMDA Suspends Review Specialist for 3 Days over Lost USB
September 28, 2026
- Japan Doles Out Orphan Tags to Givinostat, Apitegromab, and Lots More
September 28, 2026
- MHLW Pharma Chief Eyes Wider Use of English Drug Filings to Stem Drug Loss
September 25, 2026
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…